Gwladys Foouche

PARIS (Reuters) -French drugmaker Sanofi (NASDAQ) stated that it expects its COVID-19 vaccination to be approved by the FDA in the first quarter. This will help boost earnings and further growth.

This group hopes to rebound after falling in the COVID-19 jab racing.

The company’s three-month sales grew by 4.1% to 9.99 Billion Euros ($11.45Billion). Its EPS was 1.38 euro, as compared to 1.22 euros during the same quarter last.

At constant exchange rates, the earnings per share rose 15.5% for the entire 2021 period, while 14% was expected.

Sanofi lost its position as the global leader in vaccine production, even though it was the most successful manufacturer of vaccines before the COVID-19 epidemic.

Instead, it is focusing its efforts on collaboration with GlaxoSmithKline (NYSE) in developing a COVID-19 candidate vaccine. This will be based on the conventional protein-based approach. Mass trials of this vaccine are currently ongoing.

They had originally hoped to approve the agreement in 2021’s first half. But, after delays to December and the beginning of 2019, they moved the deadline to 2022’s first quarter.

Sanofi’s Chief Financial Officer stated that it expected to approve the quarter-one budget on Friday.

“We still await the final results (of trial )…). Jean-Baptiste Chasseloup de Chatillon stated to reporters that the first quarter is still pending results.

Unilever, a consumer goods company (NYSE:), offered to buy GlaxoSmithKline’s healthcare business last month at 50 billion pounds. However, it declined to increase its offer when GSK demanded a lower price.

De Chatillon indicated that although he anticipated “some consolidation” within the pharmaceutical sector, but Sanofi wouldn’t be part of this. Sanofi plans to seperate its consumer healthcare division by 2022.

De Chatillon added that they aren’t in that business, and said that company was focused on increasing the value of the division.